Candel Therapeutics Share Price Today

Candel Therapeutics Q3 loss of $(0.28) beats estimate by 20%

Candel Therapeutics reported a Q3 loss of $(0.28) per share. Result beat the analyst consensus estimate of $(0.35) by 20%. Loss widened 33.33% from $(0.21) in the same period last year.

Candel to present NSCLC and glioblastoma data at SITC 2026

Candel Therapeutics will present data on aglatimagene besadenovec and linoserpaturev at the SITC 41st Annual Meeting in November 2026. Phase 2a aglatimagene data showed median overall survival of 24.5 months in advanced NSCLC patients progressing on immune checkpoint inhibitors. Non-squamous histology subgroup achieved median overall survival of 25.4 months, with 69% of multi-lesion patients showing systemic response. Linoserpaturev poster will detail combination with VEGF blockade to overcome hypoxia-associated immune suppression in glioblastoma. Aglatimagene grade 3 treatment-related adverse events were reported in 13.7% of patients with no dose-limiting toxicities.

Candel Therapeutics CEO to present at September investor conferences

Candel Therapeutics CEO Paul Peter Tak to speak at three investor conferences in September 2026. Events include Citi Biopharma Back to School, Cantor Global Healthcare, and H.C. Wainwright conferences. Live webcasts available on company website with 90-day replay archive. Pipeline includes aglatimagene (adenovirus) and linoserpaturev (HSV) candidates.

Candel Therapeutics Q2 EPS of $(0.52) misses estimates

Candel Therapeutics reported Q2 2026 EPS of $(0.52), missing estimates of $(0.23) by 126%. The per-share loss surged 477.78% from $(0.09) in Q2 2025. Total net loss widened to $38.9 million from $4.8 million, driven by higher R&D spend and warrant liability expenses.

Candel Therapeutics grants 30,800 inducement options at $10.01

Candel Therapeutics granted 30,800 stock options at $10.01 per share to three new hires on July 31, 2026. The awards, governed by Nasdaq Rule 5635(c)(4) and the 2025 Inducement Plan, vest over four years with a 25% cliff after one year. This move supports the company's ongoing development of its multimodal immunotherapy pipeline for cancer treatment.

Candel Therapeutics to present Phase 3 prostate cancer data at ASTRO 2026

Candel Therapeutics will present extended Phase 3 data on aglatimagene besadenovec for localized prostate cancer at the ASTRO 2026 Annual Meeting in Boston. The poster, presented by CSO Francesca Barone, focuses on immune activation via quantitative digital pathology. Aglatimagene holds multiple FDA designations, including Fast Track and Regenerative Medicine Advanced Therapy, highlighting its potential in treating intermediate- to high-risk prostate cancer.